TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05646316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excisional Biopsy
Description: Undergo sentinel lymph node excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excisional Biopsy
Description: Undergo sentinel lymph node excision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Solution
Description: Given via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Solution
Description: Given via injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgery
Description: Undergo minimally invasive hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgery
Description: Undergo minimally invasive hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic Lymphadenectomy
Description: Undergo pelvic lymphadenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic Lymphadenectomy
Description: Undergo pelvic lymphadenectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Mapping
Description: Undergo sentinel lymph node mapping

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Mapping
Description: Undergo sentinel lymph node mapping
Study: NCT05373576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TACHIDINO
Description: TACHIDINO is based on two principles a) selective stimulation of a cerebral hemisphere and specific reading strategies, and b) the training of selective visuospatial attention, as well as the perception of rapid movement and the visual characteristics of words even in the presence of so-called visual crowding or crowding, an automatic effect of our perceptual system that leads to obfuscation of the visual areas surrounding the object to be analyzed, to make its vision clearer (as suggested by the Magnocellular theory of dyslexia; Stein et al., 2019).
Study: NCT05081193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Description: 198mg taken twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160mg taken once daily
Study: NCT03964025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing Cardioskin™ for 14 days
Description: The current standard of care for diagnosing AF is through the use of a 24 hour Holter device. In this study, in addition to wearing the 3-lead Holter recorder for 24 hours, the subject will be wearing the Cardioskin™ for a period of 24 hours as well, after which the subject will continue wearing the Cardioskin™ alone for an additional period of 13 days.
Study: NCT00122161

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ATHENA Decision Support System, An Automated Clinical Decision Support System for Health Care Providers

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Profiling performance
Study: NCT04436081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC-free CBD Oil
Description: Hemp-based CBD oil Gelcaps

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Gelcaps
Study: NCT05456516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Rating
Description: Children will rate foods on taste, health, and desire to eat. The order in which they rate the food characteristics is randomly assigned and counter-balanced across participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Rating
Description: Children will rate foods on taste, health, and desire to eat. The order in which they rate the food characteristics is randomly assigned and counter-balanced across participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Rating
Description: Children will rate foods on taste, health, and desire to eat. The order in which they rate the food characteristics is randomly assigned and counter-balanced across participants
Study: NCT04573231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: PSMA is highly expressed on prostate cancer and is associated with metastasis and resistance to anti-androgen therapies. Researchers have evaluated the expression of PSMA in the tumor and tumor-associated neovasculature in primary tumors and distant metastases in patients with breast cancer.
Study: NCT06488716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7759065
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7759065
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7759065
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7759065
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Specified dose on specified days
Study: NCT06542250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5492
Description: CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously
Study: NCT06061328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OASIS DA training
Description: The OASIS decision aid is a novel implementation strategy selection tool developed by a multidisciplinary team of experts using machine learning algorithms and user-centered design approaches.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current DA Tool training
Description: The CFIR-ERIC Matching Tool is a currently available decision aid tool for selecting implementation strategies that is based on expert opinion.
Study: NCT05432232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HistoSonics Investigational System
Description: The HistoSonics Investigational System is intended for the non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
Study: NCT06116916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4951
Description: KHK4951 eye drop for 36 weeks until end of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4951
Description: KHK4951 eye drop for 36 weeks until end of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4951
Description: KHK4951 eye drop for 36 weeks until end of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
Study: NCT04929496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-PCI FFR
Description: final invasive physiology measurements after successful stent implantation, followed by functional optimization if physiology indexes remain positive.
Study: NCT06518941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Study medication will be initiated at 1mg, to be taken before bed. Dosing will follow a flexible titration. The expected titration will be 1 mg for 2 weeks, 2.5 mg for 2 weeks, then 5 mg for 4 weeks. Doses may be lowered from those recommended by the protocol if side effects are significant.
Study: NCT05259033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IcoSema
Description: IcoSema once weekly subcutaneously (s.c., under the skin) using a needle and a pen.~For about 1 year and 1 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 1 mg
Description: Semaglutide once weekly subcutaneously (s.c., under the skin). Dose titrated to 1mg over 8 weeks (0.25 mg for 4 weeks, 0.5 mg for 4 weeks). For about 1 year and 1 month.
Study: NCT05115656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online group 1
Description: The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online group 2
Description: The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
Study: NCT05203237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VK2735
Description: Administered SC
Study: NCT05294848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze-Contingent Feedback Training
Description: Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification
Description: Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
Study: NCT05203237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VK2735
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VK2735 Placebo
Description: Administered orally
Study: NCT05711238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation
Description: In robot-assisted therapy, the therapist selects different programs with personalized environments to train patients to strengthen limb muscles that have previously had difficulty with movements or are relatively weak. Active (individual finger movement, memory, motility, apple tree, target board, recycling bins, balloons, firefighter), auxiliary, and passive (cpm, cpm plus) treatment options are available in the system.
Study: NCT05203237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK2735 Drug
Description: Administered orally
Study: NCT05294848

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Control
Description: Dot-probe task using only neutral stimuli with no training toward threat
Study: NCT05138120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Toolbox
Description: An unguided online single-session intervention with four modules: behavioral activation, cognitive restructuring, gratitude, and self-compassion.
Study: NCT05711238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional therapy group In the pediatric rehabilitation of the children's hands on the affected side, an exercise program consisting of 40 minutes of hand finger joint range of motion exercises (passive, active assistive), strengthening exercises, and coarse and fine dexterity exercises was planned, accompanied by a physiotherapist experienced for at least 5 years.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Description: Conventional therapy group In the pediatric rehabilitation of the children's hands on the affected side, an exercise program consisting of 40 minutes of hand finger joint range of motion exercises (passive, active assistive), strengthening exercises, and coarse and fine dexterity exercises was planned, accompanied by a physiotherapist experienced for at least 5 years.
Study: NCT04770896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of \< 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of \< 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.
Study: NCT06306430

Intervention type: DEVICE
Intervention: STANDARDTM F TB LAM FIA
Description: STANDARDTM F TB LAM Ag FIA is a fluorescent immunoassay for the qualitative detection of specific antigen from mycobacterial lipoarabinomannan (LAM) in urine specimen. STANDARDTM F TB LAM Ag FIA should be used with the STANDARD F Analyzers manufactured by SD BIOSENSOR.

Intervention type: DEVICE
Intervention: STANDARDTM F TB LAM FIA
Description: STANDARDTM F TB LAM Ag FIA is a fluorescent immunoassay for the qualitative detection of specific antigen from mycobacterial lipoarabinomannan (LAM) in urine specimen. STANDARDTM F TB LAM Ag FIA should be used with the STANDARD F Analyzers manufactured by SD BIOSENSOR.

Intervention type: DEVICE
Intervention: STANDARDTM F TB LAM FIA
Description: STANDARDTM F TB LAM Ag FIA is a fluorescent immunoassay for the qualitative detection of specific antigen from mycobacterial lipoarabinomannan (LAM) in urine specimen. STANDARDTM F TB LAM Ag FIA should be used with the STANDARD F Analyzers manufactured by SD BIOSENSOR.

Intervention type: DEVICE
Intervention: STANDARDTM F TB LAM FIA
Description: STANDARDTM F TB LAM Ag FIA is a fluorescent immunoassay for the qualitative detection of specific antigen from mycobacterial lipoarabinomannan (LAM) in urine specimen. STANDARDTM F TB LAM Ag FIA should be used with the STANDARD F Analyzers manufactured by SD BIOSENSOR.
Study: NCT06227910

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib over-encapsulated tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Upadacitinib matched placebo capsules.
Study: NCT05666102

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Transgender men's perspectives on HIV risk and HIV prevention interventions
Description: Investigators will enroll 30 TMSM in 5 focus groups where they will examine the unique contexts in which risk for HIV acquisition occurs for TMSM, and explore participant preferences for HIV prevention services. Focus group questions will focus on five areas: 1) Gathering information related to partner selection and sorting among TMSM; 2) assessing TMSM's perceptions of HIV risk in their lived experiences; 3) exploring the various types of sexual behavior TMSM are engaging in; 4) understanding the various HIV prevention strategies currently being deployed by TMSM; and 5) examine the preferences TMSM have for receiving information related to sexual health and HIV prevention information.
Study: NCT06490770

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Gait analysis, Magnetic Resonance Imaging
Description: Gait analysis and Magnetic Resonance Imaging to investigate the functionality and the pathological condition of the knee, respectively
Study: NCT05224102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Participants will receive 6-milligram (mg) faricimab intravitreal (IVT) injections, as described in the study arm descriptions for each study phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Participants will receive 6-milligram (mg) faricimab intravitreal (IVT) injections, as described in the study arm descriptions for each study phase.
Study: NCT06642441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy + vitamin D2
Description: Before the start of treatment and every 3 weeks thereafter, participants will receive a 10 mg dose of vitamin D2 injection until adjuvant chemotherapy is completed. They will receive a standard adjuvant chemotherapy regimen, which includes 10 mg of vitamin D2 injections per cycle during treatment. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: Participants will receive a standard adjuvant chemotherapy treatment regimen for each adjuvant chemotherapy cycle. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
Study: NCT06532747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Lifestyle Intervention (ILI)
Description: ILI participants will receive training in empirically supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with BWL content adapted to meet the needs of EAs.
Study: NCT06219980

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT+chemoimmunotherapy
Description: All eligible patients will receive SBRT (6Gy\*3 fractions, qod) to the primary site and metastatic lymph nodes. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics.
Study: NCT05535998

Intervention type: PROCEDURE
Intervention: TACE-HAIC
Description: The TACE-HAIC which was performed using 30 mg/m2 of epirubicin mixed with 2-5 mL lipiodol, followed by pure lipiodol. Then, a catheter was placed and fixed in the tumor feeding artery for the FOLFOX-based chemotherapy infusion at the following dosage: 85 mg/m2 of oxaliplatin infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; 400 mg/m2 of 5-FU bolus; and 2400 mg/m2 of continuous 5-FU infusion for 46 hours or 1200mg/m2 of continuous 5-FU infusion for 23 hours, respectively. Repeated TACE-HAIC was performed at intervals of 3-4 weeks.

Intervention type: PROCEDURE
Intervention: TACE
Description: TACE was performed using 30 mg/m2 of epirubicin, 200 mg/m2 of carboplatin, and 4mg/m2 of MMC, mixed with 2-5 mL lipiodol. Up to 20 mL of additional pure lipiodol were injected into the tumor-feeding artery until stasis of blood flow was observed in the target artery. Repeated TACE was performed at intervals of 3-4 weeks.

Intervention type: DRUG
Intervention: Targeted therapy
Description: The TKI therapy used in this study were lenvatinib (12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg), sorafenib (400 mg twice a day) or apatinib (250-500 mg orally once daily). Administration of lenvatinib, apatinib or sorafenib was started on the first post-TACE day, and continually administered until disease progression developed or serious treatment-related toxicity occurred.

Intervention type: DRUG
Intervention: PD-1 inhibitors
Description: PD-1 inhibitors were intravenously administered on the first post-TACE day as follows: camrelizumab 200 mg or sintilimab 200 mg or toripalimab 240 mg or tislelizumab 200 mg, every 3-4 weeks.
Study: NCT04947761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified Tian Wang Bu Xin Dan hydrogel patch
Description: modified Cheonwangbosimdan hydrogel patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: placebo patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
Study: NCT06532747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring with digital tools
Description: All participants will receive digital tools to facilitate self-monitoring-the initial 4-month program will consist of group sessions via Zoom (8 weekly, 4 bi-weekly) with weekly tailored e-coaching, followed by monthly boosters through 12 months.
Study: NCT06193759

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)
Description: Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due to significant adverse effects and are treated with intensive chemotherapy followed by autologous stem cell rescue; however, despite intensive therapy, many of these patients relapse. In this study, individualized TSA-T cells will be generated against proteogenomically determined tumor-specific antigens after standard of care treatment in children less than 5 years of age with embryonal brain tumors.
Study: NCT06318390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: XO Genius
Description: This is a beverage powder that is high in healthy ingredients that are believed to be beneficial for physiological health